

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-70. Cancelled

71. (Previously Presented): A composition containing a nucleic acid sequence encoding a polypeptide consisting of SEQ. ID NO:2, wherein said nucleic acid sequence is operably linked to a promoter, and wherein the composition elicits an adaptive immune response against hTRT (SEQ. ID NO:2) when administered to a subject.

72. (Previously Presented): A composition containing a nucleic acid sequence encoding a polypeptide comprising SEQ. ID NO:2, wherein said nucleic acid sequence is operably linked to a promoter, and wherein the composition elicits an adaptive immune response against hTRT (SEQ. ID NO:2) when administered to a subject.

73. (Previously Presented): A composition containing a nucleic acid sequence that encodes a polypeptide comprising a peptide sequence at least 98% identical to the 1132 residues of SEQ. ID NO:2, wherein said nucleic acid sequence is operably linked to a promoter, and wherein the composition elicits an adaptive immune response against hTRT (SEQ. ID NO:2) when administered to a subject.

74. (Currently Amended): A composition containing a nucleic acid sequence encoding a polypeptide consisting of at least 40 100 contiguous amino acids of SEQ. ID NO:2, wherein said nucleic acid sequence is operably linked to a mammalian promoter or mammalian viral promoter, and wherein the composition elicits an adaptive immune response against hTRT (SEQ. ID NO:2) when administered to a subject.

75. Cancelled

76. (Currently Amended): A composition containing a nucleic acid sequence encoding a polypeptide that comprises at least 10 100 contiguous amino acids of SEQ. ID NO:2, wherein said nucleic acid sequence is operably linked to a mammalian promoter or mammalian viral promoter, and wherein the composition elicits an adaptive immune response against hTRT (SEQ. ID NO:2) when administered to a subject.

77-78. Cancelled

79. (Previously Presented): A composition containing a plasmid vector encoding a polypeptide that comprises SEQ. ID NO:2, wherein when the composition is administered to a subject, the polypeptide is expressed and elicits an adaptive immune response against hTRT (SEQ. ID NO:2).

80. (Currently Amended): A composition containing a plasmid vector encoding a polypeptide that comprises at least 10 500 contiguous amino acids of SEQ. ID NO:2, wherein when the composition is administered to a subject, the polypeptide is expressed and elicits an adaptive immune response against hTRT (SEQ. ID NO:2).

81. (Previously Presented): A composition containing a plasmid vector encoding a polypeptide comprising a sequence identical to the 1132 residues of SEQ. ID NO:2, wherein when the composition is administered to a subject, the polypeptide is expressed and elicits an adaptive immune response against hTRT (SEQ. ID NO:2).

82. (Previously Presented): A composition containing a plasmid vector encoding a polypeptide comprising a peptide sequence at least 98% identical to the 1132 residues of SEQ. ID NO:2, wherein when the composition is administered to a subject, the polypeptide is expressed and elicits an adaptive immune response against hTRT (SEQ. ID NO:2).

83. (New): A composition containing a nucleic acid sequence encoding a polypeptide comprising at least 500 contiguous amino acids of SEQ. ID NO:2, wherein the

App. No. 10/044,692
Response to Office Action dated June 6, 2008

composition elicits an adaptive immune response against hTRT (SEQ. ID NO:2) when administered to a subject.

84. (New) A composition containing a nucleic acid sequence encoding a polypeptide comprising at least 500 contiguous amino acids of SEQ. ID NO:2.

85. (New): A composition containing a nucleic acid sequence encoding a polypeptide comprising a polypeptide sequence at least 98% identical to the 1132 residues of SEQ. ID NO:2.